4 results
to develop and explore measuring methods using conventional smartphones to quantify fatigue, disease activity, and short term and long progression in a day-to-day setting in patients with MS. Key research questions: - Are the NeuroKeys and MS Sherpa…
The primary objective of this study is to determine the Optical Density Ratio (ODR) for the prototype CORIMAP camera and compare the ODR values with the Oxymap T1 mounted on a regular fundus camera in a healthy adult population. For comparison, it…
ALZ-801 is an oral agent that is being developed as a potential disease modifying treatment for AD. This 78-week Phase 3 study will focus on Early AD subjects who carry the APOE4/4 genotype, and is designed according to current regulatory guidance…
Objectives - Core StudyPrimary Objectives• To evaluate the effects of oral ALZ-801 in subjects with Early AD who have the APOE4/4 or APOE3/4 genotype, on the plasma biomarkers of core AD pathology and brain volumes* Primary Plasma Biomarker Outcome…